Myriad Genetics shares fall 6.2% after Piper Sandler downgrade
Myriad Genetics shares fell 6.2% in the afternoon session after Piper Sandler double-downgraded the stock to Underweight, saying major strategic action is likely needed.
Shares of genetic testing company Myriad Genetics NASDAQ:MYGN fell 6.2% in the afternoon session after Piper Sandler double-downgraded the stock to Underweight, saying major strategic action is likely needed. Piper Sandler analyst Dave Westenberg downgraded Myriad Genetics by two steps.